Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 25, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REGN.

Regeneron Investigation Details

On May 15, 2026, Regeneron issued a press release disclosing that "results from the Phase 3 trial evaluating two dose levels of fianlimab (LAG-3 inhibitor) in combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma" "did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy." Following this news, Regeneron's stock price dropped $68.57 per share, or 9.82%, to close at $629.68 on May 16, 2026.

What's Next for Regeneron Investors?

If you are aware of any facts relating to this investigation or purchased Regeneron securities, you can assist this investigation by visiting the firm's site: bgandg.com/REGN. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Regeneron Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Regeneron Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller

Bronstein, Gewirtz & Grossman, LLC

917-590-0911 | [email protected]

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC